Date: 2014-09-29
Type of information: Presentation of results at a congress
phase: 1
Announcement: presentation of results at the 2014 Congress of the European Society for Medical Oncology (ESMO)
Company: Roche (Switzerland)
Product: MPDL3280A (atezolizumab)
Action mechanism: immunotherapy product/monoclonal antibody/immune checkpoint inhibitor. Anti-PDL1 antibody MPDL3280A is an investigational monoclonal antibody designed to make cancer cells more vulnerable to the body’s immune system by interfering with a protein called PD-L1. PD-L1 is found on the surface of cells in tumours and is believed to act as a “stop sign,” preventing the immune system from destroying cancer cells. By inhibiting PD-L1, MPDL3280A may enable the activation of T cells, restoring their ability to effectively detect and attack tumour cells. MPDL3280A is being studied in clinical trials to understand whether blocking PD-L1 will help the immune system respond to cancer.
Disease: metastatic urothelial bladder cancer
Therapeutic area: Cancer - Oncology
Country:
Trial details:
Latest news: * On September 29, 2014, Roche presented an update on data for the use of its immunotherapy, MPDL3280A (anti-PDL1 or anti Programmed Death Ligand-1) in patients with metastatic urothelial bladder cancer at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid. With increased observation time in the study, MPDL3280A showed an objective response rate (ORR) of 52% in PD-L1-positive patient populations compared with the ORR presented at ASCO 2014 (43%). MPDL3280A continued to be well tolerated.The updated results from a phase I open-label study showed the investigational cancer immunotherapy MPDL3280A shrank tumours (ORR) in 52 percent (17/33) of people who were mostly pretreated for metastatic urothelial bladder cancer and whose tumours were characterised as PD-L1 positive by a test being developed by Roche. In the overall mUBC population: • Complete responses (CRs) were observed in three patients • 19 of 22 (86 percent) responding patients had ongoing responses at the time of data cutoff • The median duration of response was not reached • Median progression-free survival (PFS) in PD-L1 positive patients treated with MPDL3280A was 24 weeks and was longer than median PFS in PD-L1 negative patients which was 8 weeks.
